> 首页 > 产品 > 一抗 > 其他 > Anti-PD-1 & TIGIT Reference Antibody (Rilvegostomig）

Anti-PD-1 & TIGIT Reference Antibody (Rilvegostomig）

Anti-PD-1 & TIGIT Reference Antibody (Rilvegostomig）on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-PD-1 & TIGIT Reference Antibody (Rilvegostomig）is 95.78%, determined by SEC-HPLC.
To measure the binding ability of Rilvegostomig in Human TIGIT-his. Rilvegostomig bound to TIGIT protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig 3, Rilvegostomig bound to Human TIGIT-his, and the EC50 was 0.040 nM.
To measure the binding ability of Rilvegostomig in Hu-PD1-his. Rilvegostomig bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig 4, Rilvegostomig bound to HuPD-1-his, and the EC50 was 0.011 nM.
The detected weight of Anti-PD-1 & TIGIT Reference Antibody (Rilvegostomig) is 145.78 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q15116 & Q495A1
Reactivity	Human
Clonality	Bispecific
Isotype	IgG-like

Additional Information
Target/Specificity	PDCD1 / PD-1 / CD279,TIGIT / VSIG9 / VSTM3
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.